Safety and PK of Atrosimab in Healthy Volunteers

Phase 1, randomised, double-blind trial in chronic liver disease (CLD) and Nonalcoholic steatohepatitis (NASH) comparing ATM001 with Placebo (2 arms). Primary endpoints: Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time at 8 days, Area under the plasma concentration curve from administration until the last quantifiable sampling point at 8 days and 7 more. Started Jul 2021; status: completed.